NR3C1 and prostate carcinoma: Interestingly, HO-1 overexpression has recently been reported to negatively modulate glucocorticoid receptor pathways in prostate cancer cells [86], and glucocorticoids (prednisone and dexamethasone) play an essential role in the treatment of acute lymphoblastic leukemia (ALL) [87].